Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

LCTX vs VTGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LCTX Captures Overall Composite Edge (58.9 HOLD vs 46.5 HOLD), While VTGN Leads 3–2 on Growth & Valuation Pillars

LCTX Overall Winner 6-Pillar Tally: LCTX 2 – 3 VTGN (1 Tie) Matrix Metrics: LCTX 9 – 1 VTGN

As of Nov 19, 2026, Lineage Cell Therapeutics, Inc. (LCTX) captures the overall head-to-head institutional edge over Vistagen Therapeutics, Inc. (VTGN) on higher Unified Composite conviction (58.9/100 HOLD vs. 46.5/100 HOLD) after splitting the core matrix 9–1 (led by Valuation Multiples, Profitability & Quality), while VTGN wins 3–2 across the 6-pillar growth and valuation breakdown. LCTX trades at $0.82 (30.7x Forward P/E, -280.3% operating margin) versus VTGN at $0.19 (N/M Forward P/E, -2543.1% operating margin).

  • Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (58.9/100 HOLD vs. VTGN 46.5/100 HOLD) and 1.36β · 79% Vol risk profile, whereas VTGN leads top-line expansion (-46.5% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3); meanwhile VTGN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 49.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LCTX vs VTGN
LCTX NYSE American Head-to-Head Winner
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.36β · 79% Vol
Unified Composite Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.2%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $0.98 · SMA50: $0.98
VTGN NASDAQ
Vistagen Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.19
-6.47% 1D
Market Cap $9.0M
TTM Revenue $2.4M
Forward P/E N/M
Beta / 30D Vol 1.23β · 80% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 30.0 Fund 60.0 Flow 69.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.1 · SMA20: $0.18 · SMA50: $0.22

6-Pillar Scorecard Institutional Category Breakdown (LCTX 2 – 3 VTGN)

Columns: Metric · LCTX · VTGN
1. Valuation Multiples LCTX
Forward P/E 30.7x N/M
Trailing P/E 30.7x N/M
PEG Ratio 10.64x N/M
EV / Revenue 16.3x N/M
2. Growth & Scale VTGN
Revenue Growth (YoY) -61.0% -46.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M $2.4M
Market Cap $212.1M $9.0M
3. Profitability & Quality LCTX
Gross Margin -95.0% 100.0%
Operating Margin -280.3% -2543.1%
Net Profit Margin 16.2% 0.0%
Return on Equity (ROE) 4.3% -144.9%
4. Balance Sheet & Cash Flow VTGN
Cash Generation (TTM) -$24M -$60M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $35M Net Cash $30M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VTGN
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 896.2% (100th %ile) 274.8% (71st %ile)
Put/Call OI Skew 1.10x (Balanced) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LCTX (9) vs VTGN (1)
Institutional Metric LCTX VTGN Criterion Row Edge
Market Capitalization
Scale
$212.1M $9.0M Larger Scale LCTX
Trailing P/E Ratio
Valuation
30.7x N/M Lower Multiple LCTX
Forward P/E Ratio
Valuation
30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY)
Growth
-61.0% -46.5% Higher Growth VTGN
Operating Margin (TTM)
Profitability
-280.3% -2543.1% Higher Margin LCTX
Net Profit Margin
Profitability
16.2% 0.0% Higher Margin LCTX
Return on Equity (ROE)
Capital Efficiency
4.3% -144.9% Higher ROE LCTX
52-Week Range Position
Momentum
4% ($1–$2) 0% ($0–$5) Stronger Trend LCTX
Beta / 30D Volatility
Risk Regime
1.36β · 79% Vol 1.23β · 80% Vol Lower Realized Risk LCTX
Unified Institutional Score
Composite Signal
58.9 / 100 (HOLD) 46.5 / 100 (HOLD) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
$11M $2.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-95.0% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
10.64x PEG · 16.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($35M Net Cash) -$60M EBITDA ($30M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VTGN +10.2 pp
LCTX: -13.82% · VTGN: -3.62%
3M Horizon VTGN +0.55 pp
LCTX: -24.07% · VTGN: -23.52%
6M Horizon LCTX +32.83 pp
LCTX: -37.88% · VTGN: -70.71%
1Y Horizon LCTX +42.3 pp
LCTX: -53.67% · VTGN: -95.97%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LCTX Revenue VTGN Revenue LCTX Op. Margin VTGN Op. Margin Margin Leader
FY2019 $0M N/A -1106.0% N/A LCTX
FY2020 $0M N/A -1448.4% N/A LCTX
FY2021 $0M $0M -1133.6% -1646.1% LCTX
FY2022 $10M $0M -153.2% -4308.3% LCTX
FY2023 $10M N/A -276.5% N/A LCTX
FY2024 $10M $0M -226.1% -3103.5% LCTX
FY2025 $10M $0M -251.6% -11517.1% LCTX
FY2026 N/A $0M N/A -5683.7% VTGN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LCTX BREAKDOWN
6d in phase · OBV DISTRIBUTION
Current IV 896.2%
IV Percentile 100th %ile
Put/Call OI Skew 1.10x (Balanced)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VTGN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 274.8%
IV Percentile 71st %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VTGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $212.1M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VTGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.0M market capitalization and -2543.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LCTX vs VTGN Key Questions & Quantitative Answers

As of Nov 19, 2026, Lineage Cell Therapeutics, Inc. (LCTX) captures the overall head-to-head institutional edge over Vistagen Therapeutics, Inc. (VTGN) on higher Unified Composite conviction (58.9/100 HOLD vs. 46.5/100 HOLD) after splitting the core matrix 9–1 (led by Valuation Multiples, Profitability & Quality), while VTGN wins 3–2 across the 6-pillar growth and valuation breakdown. LCTX trades at $0.82 (30.7x Forward P/E, -280.3% operating margin) versus VTGN at $0.19 (N/M Forward P/E, -2543.1% operating margin). Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (58.9/100 HOLD vs. VTGN 46.5/100 HOLD) and 1.36β · 79% Vol risk profile, whereas VTGN leads top-line expansion (-46.5% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3); meanwhile VTGN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 49.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VTGN leads the Growth & Scale pillar: LCTX posts -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin), compared with VTGN at -46.5% YoY revenue growth and +0.0% YoY earnings growth on $2.4M TTM revenue (100.0% gross margin, -2543.1% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), LCTX cumulative revenue shifted +0.0% while VTGN shifted N/A. In operating R&D and SG&A reinvestment, LCTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VTGN.

LCTX screens cheaper on headline valuation multiples. LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 16.3x EV/Revenue (unreported FCF margin), whereas VTGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LCTX (4.3% ROE) versus VTGN (-144.9% ROE) capital efficiency.

In options market volatility and institutional positioning, LCTX carries 896.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 1.10x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 79% Vol realized risk). By comparison, VTGN carries 274.8% implied volatility (71st %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.23β · 80% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.